Boston Scientific said it's reached an agreement to acquire Nalu Medical, a medtech company developing and commercializing medical implants for treating chronic pain.
Boston Scientific has been a strategic investor in Nalu Medical since 2017. The transaction consists of an upfront cash payment of approximately $533 million for the remaining equity not owned by Boston Scientific.
The Nalu Neurostimulation System is designed to deliver targeted relief for adults living with severe, intractable chronic pain of peripheral nerve origin, including areas such as the shoulder, lower back and knee, through peripheral nerve stimulation (PNS). The therapy uses mild electrical impulses to interrupt pain signals before they reach the brain. The system features a miniaturized, battery-free implantable pulse generator, powered wirelessly by a small, externally worn therapy disc and controlled via a smartphone app.
Nalu Medical received FDA clearance for the Nalu system in 2019.
"Peripheral nerve stimulation is an exciting field with a significant unmet patient need," said Jim Cassidy, president of the neuromodulation unit at Boston Scientific, in a statement. "Adding the highly differentiated Nalu Medical technology complements our existing therapies—including spinal cord stimulation, basivertebral nerve ablation and radiofrequency ablation—enabling us to deliver advanced pain relief options to a wider variety of patient populations."
Boston Scientific expects to complete the transaction in the first half of 2026.
